Real-World Evidence of the Long-Term Effectiveness of 0.2 μg/Day Fluocinolone Acetonide Implant in Persistent and Recurrent Diabetic Macular Edema - A Single Center Study.
Ricardo Machado SoaresCatarina Cunha FerreiraJoana da Silva FernandesCarolina MadeiraLuís M A SilvaEduardo SaraivaLígia RibeiroSofia FonsecaPublished in: Clinical ophthalmology (Auckland, N.Z.) (2024)
Our results support the effectiveness and safety profile of fluocinolone acetonide. Although additional long-term real-world evidence is required, fluocinolone acetonide may represent a safe strategy for daily, low-dose, sustained and localized release to the posterior segment of the eye, providing both functional and anatomical benefits in DME.
Keyphrases